• The 100th Aeson® heart implant was performed;
• CARMATA was liquidated;
• Acquisition by Pierre Bastid, the new president of CARMAT SAS.​

• Annual revenue of 7 M€ (42 Aeson® artificial hearts);
• First European meeting of Aeson® users, bringing together more than 100 cardiology experts

• Commissioning of a second production facility in Bois-d’Arcy;
• Aeson has surpassed the milestone of 50 locations since its inception

• Sales Pick Up in Europe;
• Launch of the EFICAS Study in France

• First sales in Europe;
• Launch of a feasibility study in the United States;
• Temporary voluntary suspension of Aeson’s installations following the identification of quality issues

Aeson^® Receives CE Marking as a Bridge-to-Transplant (BTT) Therapy

Certification and Commissioning of the Bois-d’Arcy Production Facility (France)

Début de l’étude PIVOTAL en Europe

First Implantation of the Aeson® Artificial Heart as Part of a Feasibility Study in France

Founding of CARMAT